Clinical Trial of Teriparatide in Japan
Phase 2
Completed
- Conditions
- Osteoporosis
- Registration Number
- NCT00191867
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to assess the Efficacy and Safety of Teriparatide in Japanese Postmenopausal Women with Osteoporosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 160
Inclusion Criteria
- Japanese women with primary osteoporosis
- Postmenopausal women aged at least 55 years
- Patients with a high risk for fracture
Read More
Exclusion Criteria
- History of metabolic bone disorders other than osteoporosis
- History of any secondary causes of osteoporosis
- History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated
- Severe or chronically disabling conditions other than osteoporosis
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To assess the dose response of LY333334 with the percent change from baseline in lumbar spine mineral density at endpoint
- Secondary Outcome Measures
Name Time Method To evaluate the safety of LY333334
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
🇯🇵Tokyo, Japan